World's Third Largest Pharmaceutical Company Plans Move to
Nearby Bridgewater, NJ, Site to Accommodate Growth
BRIDGEWATER, N.J., Nov. 7 /PRNewswire-FirstCall/ -- The Sanofi-aventis
Group announced today that it has signed an agreement to move its U.S.
headquarters from its current location at Somerset Corporate Center in
Bridgewater to 55 Corporate Drive, also in Bridgewater, to combine the
headquarters activities into one location and to support future growth.
Financial details of the agreement were not disclosed.
The move is scheduled to begin in December 2005. The three-building
complex at 55 Corporate Drive is situated on 150 acres on Route 206 near
Interstates 287 and 78. The current plans call for a total reconfiguration of
the interior space of the existing buildings. Full occupancy of the
approximately 670,000 square feet is expected by the end of 2006.
A joint venture between The Gale Company, SL Green and a client of
Principal Real Estate Investors acquired the 55 Corporate Drive office complex
from AT&T Corporation earlier this year.
"The new site was chosen because it can accommodate our business needs for
a more flexible and integrated space," says Tim Rothwell, President and CEO of
sanofi-aventis U.S. "In addition, we wanted to remain in the Bridgewater
vicinity to accommodate our more than 3,800 sanofi-aventis employees from
various divisions who currently work in the area. The site was a perfect
choice."
Sanofi-aventis currently maintains three sites in Bridgewater; Somerset
Corporate Center, Bridgewater Crossings and the Science & Medical Affairs
(S&MA) campus facility. Following completion of the move, all U.S.
Pharmaceutical Operations employees will be located at the new site. Somerset
Corporate Center will house an expanded Sales Training Center, the Northeast
Regional Sales Office, and Global employees. The S&MA Campus and the
Bridgewater Crossings facilities will be dedicated to S&MA activities.
About sanofi-aventis
The sanofi-aventis Group is the world's third largest pharmaceutical
company, ranking number one in Europe. Backed by a world-class R&D
organization, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases,
central nervous system, internal medicine, and vaccines. The sanofi-aventis
Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi-aventis Group subsidiaries in the United States include
Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.
Contact: Marc Greene, sanofi-aventis
212-551-4400 or 908-243-42643
Michael Beckerman, for The Gale Company
908-781-6420
SOURCE sanofi-aventis
 back to top
Related links:
http://www.sanofi-aventis.com
Company News On-Call:
http://www.prnewswire.com/comp/232375.html
CONTACT:
Marc Greene, sanofi-aventis, +1-212-551-4400
or +1-908-243-42643; or Michael Beckerman, for The Gale Company,
+1-908-781-6420
|
